CompletedPhase 4

Envarsus Neurotoxicity Burden in Liver Transplant Patients

United States30 participantsStarted 2020-01-31

Plain-language summary

This study will compare neurologic side effects associated with two immunosuppressant medications used in liver transplant patients. The standard therapy of twice daily immediate release Tacrolimus will be compared to Envarsus once daily. We hypothesize that Envarsus will show a lower rate of neurologic side effects than immediate release tacrolimus.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Male or female adult (≥18 years old) with a history of liver or liver/kidney transplant within the first 6 months of transplant.
✓. Patients must be capable of understanding the purposes and risks of the study and have the ability to give written informed consent and be willing to participate and comply with the study.

Exclusion criteria

✕. Patients will be excluded if they are pregnant or nursing females or males with a pregnant female partner
✕. HIV positive (HIV ab +)
✕. Unable to tolerate oral medications
✕. Use of another investigational product within thirty days prior to receiving study medication
✕. Moderate acute cellular rejection (RAI ≥ 5) within the past month
✕. A condition that is known to cause tremor such as essential tremor, Parkinson disease, or enhanced physiologic tremor.
✕. Patients taking medications known to induce tremors or dopamine blocking agents
✕. A condition or disorder that, in the opinion of the investigator, may adversely affect the outcome of the study or the safety of the subject

What they're measuring

Change in Neurotoxicity Burden

Timeframe: 6 months

Trial details

NCT IDNCT03823768

SponsorMedical University of South Carolina

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2023-04-30

Results submitted2024-04-10

View on ClinicalTrials.gov More Neurotoxicity trials